ClinicalTrials.gg
Not yet recruitingNCT07843901ALPSUpdated Sep 28, 2026

Lenvatinib in Patients With Advanced Parathyroid Carcinoma

A Phase 2 interventional study of Lenvatinib in Parathyroid Carcinoma, sponsored by Yonsei University. Not yet recruiting. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Yonsei University · Phase 2, Interventional, and Treatment

Updated Sep 28, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

This is a multicenter, open-label, single-arm, phase II study evaluating the efficacy and safety of lenvatinib in patients with unresectable, advanced or metastatic parathyroid carcinoma.

Parathyroid carcinoma is a rare malignant tumor with limited systemic treatment options in patients with unresectable, recurrent, or metastatic disease. Excessive secretion of parathyroid hormone (PTH) and resulting hypercalcemia may cause significant morbidity and adversely affect prognosis and quality of life. Although complete surgical resection is considered the only potentially curative treatment for localized disease, no established standard systemic therapy is currently available for advanced or metastatic parathyroid carcinoma.

Lenvatinib is an oral multikinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptor alpha (PDGFRα), RET, and KIT. Inhibition of these signaling pathways may suppress tumor angiogenesis and tumor cell proliferation. Based on the potential role of angiogenic signaling in parathyroid carcinoma and the antitumor activity of lenvatinib demonstrated in various solid tumors, lenvatinib is being investigated as a potential treatment option for advanced or metastatic parathyroid carcinoma.

A total of 18 participants will be enrolled, including consideration of potential evaluability and dropout. Eligible participants must have histologically or cytologically confirmed parathyroid carcinoma that is unresectable, advanced, or metastatic, with at least one measurable lesion according to RECIST version 1.1. Participants must be at least 19 years of age and have an ECOG performance status of 0 or 1 with adequate bone marrow, renal, and hepatic function.

Lenvatinib will be administered orally once daily at a starting dose of 24 mg. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, or another protocol-defined reason for treatment discontinuation. Dose interruption or reduction to 20 mg, 14 mg, and 10 mg once daily may be implemented for treatment-related toxicities according to the protocol and applicable local prescribing information.

The primary objective is to evaluate the objective response rate (ORR), defined as the proportion of participants achieving a complete response (CR) or partial response (PR) according to RECIST version 1.1. Secondary objectives include evaluation of progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and the safety and tolerability of lenvatinib. Exploratory objectives include assessment of changes in corrected serum calcium and PTH levels and exploration of associations between biochemical changes and clinical outcomes such as ORR and PFS.

Tumor response will be assessed according to RECIST version 1.1. Baseline imaging will be performed within 28 days before the first dose of study treatment. Tumor assessments will be performed every 8 weeks (±7 days) through Week 48 and every 12 weeks (±14 days) thereafter. Safety assessments will include adverse events, clinical laboratory tests, vital signs, physical examinations, ECOG performance status, and electrocardiograms.

The overall study period is planned for 3 years, with participant enrollment from July 1, 2026, through June 30, 2028. Each participant will be followed for up to 12 months after treatment discontinuation, or until study completion, as applicable.

The study is designed to evaluate whether lenvatinib provides clinically meaningful antitumor activity and an acceptable safety profile in patients with advanced or metastatic parathyroid carcinoma, while also exploring potential changes in calcium and PTH levels as disease-related biochemical outcomes.

02

Conditions studied

  • Parathyroid Carcinoma

Browse trials for

03

In context

Parathyroid Neoplasms

63 studies on the registry are indexed under Parathyroid Neoplasms; 19 are open to participants now.

This study's planned enrollment of 18 is below the median of 60 across 38 interventional studies indexed under Parathyroid Neoplasms.

Browse Parathyroid Neoplasms studies →

Lead sponsor

Yonsei University is the lead sponsor of 1,420 studies on the registry; 242 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following inclusion criteria prior to enrollment in the clinical trial:

  1. Parathyroid carcinoma confirmed by histopathological or cytological examination.
  2. Unresectable advanced or disease:

    1. Primary or locally recurrent lesions that extensively involve major blood vessels, the airway, or other critical organs, making curative surgical resection infeasible.
    2. Presence of multiple distant metastases (e.g., lung, liver, or bone) that preclude curative surgical resection.
    3. Additional curative surgical resection considered difficult due to repeated disease recurrence.
    4. Curative surgical resection considered inappropriate by the investigator due to the participant's general condition, comorbidities, or other clinical considerations.
  3. At least one according to version 1.1.
  4. Age ≥19 years at the time of .
  5. performance status of 0 or 1.
  6. Adequate organ and bone marrow function, as demonstrated by all of the following screening laboratory criteria:

    1. (ANC) ≥1,500/mm³.
    2. count ≥100,000/mm³.
    3. ≥9 g/dL.
    4. (ALT) and aspartate aminotransferase (AST) ≤3 × the (ULN); ≤5 × ULN in participants with liver metastases.
    5. Total ≤1.5 × ULN; ≤3 mg/dL is permitted in participants with Gilbert syndrome.
    6. Serum creatinine ≤2.5 × ULN or estimated (eGFR) ≥30 mL/min/1.73 m², calculated using the CKD-EPI equation.
    7. Urine protein-to-creatinine ratio (UPCR) ≤1 mg/mg or 24-hour urine protein \<1 g.
  7. Participants who understand the purpose and procedures of the clinical trial and voluntarily provide written informed consent.
  8. Sexually active participants of and their partners who agree to use adequate (e.g., male or female condoms).
  9. Female participants of childbearing potential must have a negative pregnancy test at screening. Women who have had menstruation within the preceding 12 months will be considered to be of childbearing potential. Amenorrhea due to anticancer treatment, hormonal suppression, low body weight, or other causes may also be considered consistent with childbearing potential.

Exclusion criteria

Exclusion Criteria

Participants meeting any of the following criteria will be excluded from participation in the study:

  1. Prior treatment with lenvatinib for advanced or parathyroid carcinoma.
  2. Treatment with another medicinal product within 14 days before the first administration of the study drug.
  3. Radiation therapy for bone metastases within 7 days before initiation of study treatment, or other external beam radiation therapy within 14 days before initiation of study treatment.
  4. Active . However, untreated asymptomatic and stable brain metastases, or brain metastases that have been adequately treated with radiation therapy or surgery (e.g., radiosurgery), are permitted if the brain metastases have remained stable for at least 14 days before initiation of study treatment and no neurological symptoms are present at enrollment.
  5. Uncontrolled or comorbidities, including any of the following:

    1. Clinically significant cardiovascular disease occurring within 6 months before initiation of study treatment:

      • Symptomatic congestive heart failure, unstable angina, or severe arrhythmia.
      • Uncontrolled hypertension despite appropriate treatment, defined as systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg.
      • Clinically significant and unresolved stroke, myocardial infarction, other ischemic events, or thromboembolic events (e.g., deep vein thrombosis or pulmonary embolism) occurring within 3 months before initiation of study treatment.
    2. Gastrointestinal disease or conditions associated with an increased risk of gastrointestinal perforation or fistula:

      • Gastrointestinal tumor invasion, active peptic ulcer disease, inflammatory bowel disease, diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, or acute pancreatitis.
      • Pancreatic or biliary duct obstruction, or gastric outlet obstruction.
      • Intra-abdominal fistula, gastrointestinal perforation, intestinal obstruction, or intra-abdominal abscess occurring within 6 months before initiation of study treatment. Participants with completely resolved conditions may be eligible.
    3. Gross hematuria, hematemesis, or hemoptysis of ≥0.5 teaspoon (approximately 2.5 mL) within 3 months before initiation of study treatment, or a history of other significant bleeding (e.g., pulmonary hemorrhage).
    4. Radiographic evidence of cavitary pulmonary lesions or endobronchial lesions.
    5. Lesions involving major pulmonary blood vessels.
    6. Other clinically significant medical conditions, including:

      • Active infection requiring systemic treatment, infection, or AIDS-related illness. Participants with virus (HBV) infection that is stable during or after antiviral treatment, or participants with virus (HCV) infection may be eligible.
      • Clinically significant unhealed wounds, ulcers, or fractures.
      • Malabsorption syndrome.
      • Moderate or severe hepatic impairment corresponding to class B or C.
      • History of organ transplantation.
  6. Major surgery (e.g., gastrointestinal surgery) within 28 days before initiation of study treatment, or unresolved complications from previous surgery.
  7. interval using the Fridericia formula (QTcF) >500 msec.
  8. Women who are pregnant or breastfeeding.
  9. Inability to take oral medications in tablet or capsule form.
  10. History of allergy or to any component of the study drug.
  11. Diagnosis of another within 3 years before initiation of study treatment. Exceptions include non-melanoma skin cancer, completely resected stage I breast cancer, completely resected carcinoma in situ or non-muscle-invasive bladder cancer, cervical and/or uterine carcinoma, or T1a squamous cell carcinoma of the esophagus.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Lenvatinib monotherapy.

    Advanced or metastatic parathyroid cancer patients will receive lenvatinib monotherapy.

    Drug: Lenvatinib

Interventions

  • This clinical trial evaluates the efficacy and safety of lenvatinib monotherapy in patients with advanced or metastatic parathyroid cancer. Lenvatinib will be administered orally at a dose of 24 mg once daily, with each cycle consisting of 3 weeks, and treatment will continue until disease progression or unacceptable toxicity. In the event of adverse events, treatment may be temporarily interrupted or the dose may be reduced according to the investigator's judgment and the study protocol.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Objective Response Rate (ORR) is defined as the percentage of participants who achieve a confirmed Complete Response (CR) or Partial Response (PR) at least once according to RECIST version 1.1 before evidence of disease progression. ORR will be summarized in the efficacy-evaluable population and presented with a two-sided 95% confidence interval.

    Time frame: End of trial(approximately 3 years)

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Progression-Free Survival (PFS) is defined as the time from the date of the first administration of the investigational medicinal product to the date of disease progression or death from any cause, whichever occurs first. PFS will be analyzed in the efficacy-evaluable population.

    Time frame: End of trial(approximately 3 years)

  2. Overall Survival (OS)

    Overall Survival (OS) is defined as the time from the date of the first administration of the investigational medicinal product to the date of death from any cause. OS will be analyzed in the safety analysis population and presented using Kaplan-Meier curves. The number and percentage of participants who died, remained alive, were lost to follow-up, or withdrew consent will be appropriately summarized.

    Time frame: End of trial(approximately 3 years)

  3. Duration of Response (DoR)

    Duration of Response (DoR) is defined as the time from the date of the first documented confirmed response to the date of disease progression or death, whichever occurs first. The start of response is defined as the date of the most recent visit at which PR or CR was confirmed. For participants who achieve a response and do not subsequently experience disease progression, the date of PFS censoring will be used to calculate the duration of response. DoR will be analyzed in the subset of the efficacy-evaluable population whose best overall response is a confirmed CR or PR. Kaplan-Meier curves and the median duration of response estimated using the Kaplan-Meier method will be presented.

    Time frame: End of trial(approximately 3 years)

  4. Disease Control Rate (DCR)

    Disease Control Rate (DCR) is defined as the percentage of participants whose best overall response (BOR), assessed according to RECIST version 1.1, is Complete Response (CR), Partial Response (PR), or Stable Disease (SD). DCR will be summarized in the efficacy-evaluable population and presented with a two-sided 95% confidence interval.

    Time frame: End of trial(approximately 3 years)

  5. Treatment-Emergent Adverse Events

    Treatment-emergent adverse events will be assessed in all participants who receive at least one dose of lenvatinib. Adverse events will be graded according to CTCAE version 5.0 and summarized by incidence, severity, and type.

    Time frame: End of trial(approximately 3 years)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Aug 2028, 21 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2026
First posted
Sep 28, 2026
StartEst.
Nov 2026
Primary completionEst.
Aug 2028
CompletionEst.
Aug 2029
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07843901
Lead sponsor
Yonsei University
Responsible party
Chang Gon Kim (Principal Investigator, Yonsei University) — Principal investigator
First posted
Sep 28, 2026
Start date
Nov 2026 (estimated)
Primary completion
Aug 2028 (estimated)
Completion
Aug 2029 (estimated)
Last update
Sep 28, 2026

Study contacts

Chang Gon Kim
Contact
inspector@yuhs.ac
82-10-9162-1729
CHANG Gon KIM
principal investigator · Yonsei University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion